JAK1 and COVID-19: An example of a successful combinatorial antiviral therapy and immunomodulatory approach is Remdesivir and Barcitinib (JAK-1 inhibitor), which has been shown to be effective in reducing clinical severity and mortality rates in COVID-19 patients [58].